Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy. Issue 10 (27th July 2015)

• Record Type: Journal Article
• Authors: Zhang, Fenghua; Sturgis, Erich M.; Sun, Yan; Zhang, Yang; Wei, Qingyi; Zhang, Caiyun; Zheng, Hongliang; Li, Guojun
• Is Part Of: International journal of cancer. Volume 137:Issue 10(2015:Nov. 15)
• Page Start: 2454
• Page End: 2461
• Publication Date: 2015-07-27
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.29604
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Single nucleotide polymorphisms (SNPs) in the promoter region of <italic>FAS</italic> and <italic>FASLG</italic> may alter their transcriptional activity. Thus, we determined the associations between four <italic>FAS</italic> and <italic>FASLG</italic> promoter variants (<italic>FAS</italic>1377G>A, rs2234767; 670A>G, rs1800682; <italic>FASLG</italic>844T>C, rs763110 and 124A>G, rs5030772) and the risk of recurrence of squamous cell carcinoma of the oropharynx (SCCOP). We evaluated the associations between <italic>FAS</italic> and <italic>FASLG</italic> genetic variants and the risk of recurrence in a cohort of 1, 008 patients. The log‐rank test and multivariate Cox models were used to evaluate the associations. Compared with patients with common homozygous genotypes of <italic>FAS</italic>670 and <italic>FASLG</italic>844 polymorphisms, patients with variant genotypes had lower disease‐free survival rates (log‐rank <italic>p</italic> < 0.0001 and <italic>p</italic> < 0.0001, respectively) and an approximately threefold higher risk of SCCOP recurrence (HR, 3.2;95% CI, 2.2–4.6; and HR, 3.1; 95% CI, 2.2–4.4, respectively) after multivariate adjustment. Furthermore, among patients with HPV16‐positive tumors, those with variant genotypes of these two polymorphisms had lower disease‐free survival rates (log‐rank, <italic>p</italic> < 0.0001 and <italic>p</italic> < 0.0001, respectively) and a higher recurrence risk than did patients with common homozygous genotypes (HR, 12.9; 95% CI, 3.8–43.6; and HR, 8.1; 95% CI, 3.6–18.6, respectively), whereas no significant associations were found for <italic>FAS</italic>1377 and <italic>FASLG</italic>124 polymorphisms. Our findings suggest that <italic>FAS</italic>670 and <italic>FASLG</italic>844 polymorphisms modulate the risk of recurrence of SCCOP, particularly in patients with HPV16‐positive tumors. Larger studies are needed to validate these results.</p> </abstract>